Treatment tactics for patients with oral mucosal cancer - Gelfand, Igor
19,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
  • Broschiertes Buch

The overall 5-year survival rate in patients with T1-2 stage oral squamous cell carcinoma ranges from 40 to 70%. Treatment options include surgery, radiation therapy, and a combination of therapies. Radiation therapy alone in the treatment of oral tumors includes intrathecal irradiation and combined radiation therapy. An alternative to radiation therapy is currently surgical treatment at the first stage with pathomorphological evaluation of the removed macroparietal specimen and possible postoperative radiation therapy if there are aggravating factors in the prognosis. The 5-year survival rate…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
The overall 5-year survival rate in patients with T1-2 stage oral squamous cell carcinoma ranges from 40 to 70%. Treatment options include surgery, radiation therapy, and a combination of therapies. Radiation therapy alone in the treatment of oral tumors includes intrathecal irradiation and combined radiation therapy. An alternative to radiation therapy is currently surgical treatment at the first stage with pathomorphological evaluation of the removed macroparietal specimen and possible postoperative radiation therapy if there are aggravating factors in the prognosis. The 5-year survival rate of patients with squamous cell carcinoma of the oral mucosa is halved in case of metastatic lesion of regional lymph nodes. In the absence of prophylactic treatment of lymph drainage zones during dynamic observation the frequency of regional metastases realization is 25-50%. The development of treatment tactics for patients with early-stage oral cancer (T1-2), with an assessment of prognostic factors, is relevant.
Autorenporträt
Gelfand Igor Mikhailovich, geboren 1985, schloss 2008 sein Studium der Allgemeinmedizin an der Nördlichen Staatlichen Medizinischen Universität in Archangelsk ab. Seit 2011 arbeitet er in der Abteilung für Kopf- und Halstumore am Wissenschafts- und Forschungszentrum N.N. Blokhin. Im Jahr 2016 verteidigte sie ihre Dissertation für den Abschluss als Kandidatin der medizinischen Wissenschaften.